share_log

Goldman Sachs Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $27

Benzinga ·  Mar 25 15:38

Goldman Sachs analyst Andrea Tan maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target from $39 to $27.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 307

Recommended

Write a comment